Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 9/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468494 | 1.00 | CYP2D6 (0.53) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1260631 | 1.00 | CYP2D6 (0.53) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| Ammonia Solution, Strong SCHEMBL27642892 | 0.98 | CYP2D6 (0.51) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| 3-Hydroxybutyric Acid, (+/-)- SCHEMBL31533997 | 0.92 | CYP2D6 (0.47) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL34471491 | 0.88 | CYP2D6 (0.45) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL6154559 | 0.83 | CYP2D6 (0.50) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL2690899 | 0.83 | CYP2D6 (0.55) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1260230 | 0.83 | CYP2D6 (0.47) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL6503240 | 0.83 | CYP2D6 (0.47) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL6545357 | 0.83 | CYP2D6 (0.47) | CYP2D6HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102199633-B | Method for preparing (S)-(+)-3-hydroxyl tert-butyl butyrate by biotransformation | UNIV ZHEJIANG TECHNOLOGY | 2013-04-17 | — | — | CN | claimed |
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2012-02-16 | — | — | US | claimed |
| CN-102199633-A | Method for preparing (S)-(+)-3-hydroxyl tert-butyl butyrate by biotransformation | UNIV ZHEJIANG TECHNOLOGY | 2011-09-28 | — | — | CN | claimed |
| US-20070185346-A1 | Kit for automated resolving agent selection and method thereof | VAIDYA NITEEN A | 2007-08-09 | — | — | US | claimed |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCE INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4440701-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-113652407-B | Carbonyl reductase mutant and application thereof in asymmetric synthesis of chiral compound | 浙江工业大学 | 2024-01-16 | — | — | CN | disclosed |
| US-20230212148-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023102523-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230105745-A1 | CYCLOALKYL AND HETERO-CYCLOALKYL INHIBITORS, PREPARATION METHODS THEREFOR, AND USE THEREOF | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-04-06 | — | — | US | disclosed |
| US-11459327-B1 | Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and use thereof | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2022-10-04 | — | — | US | disclosed |
| EP-1981831-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | Vaidya, Niteen A. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007092264-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185346-A1 | Kit for automated resolving agent selection and method thereof | VAIDYA NITEEN A | 2007-08-09 | — | — | US | disclosed |
| US-6384228-B2 | EPIBATIDINE; ANALGESICS; ANIMAL EXTRACTS | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| US-20020010339-A1 | METHOD FOR SYNTHESIS OF HALOPYRIDYL-ACYCLOPENTANE DERIVATIVE AND INTERMEDIATE THEREOF | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-01-24 | — | — | US | disclosed |
| EP-0266217-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | CHISSO CORPORATION (JP) | 1992-12-30 | — | — | EP | disclosed |
| US-4916074-A | ENZYMATIC TRANS ESTERIFICATION OF ALCOHOL WITH TRIGLYCERIDES; PSEUDOMONAS-DERIVED ENZYME | CHISSO CORPORATION (JP) | 1990-04-10 | — | — | US | disclosed |
| EP-0266217-A2 | Process for producing optically active compounds | CHISSO CORPORATION (JP) | 1988-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010339-A1 | METHOD FOR SYNTHESIS OF HALOPYRIDYL-ACYCLOPENTANE DERIVATIVE AND INTERMEDIATE THEREOF | DHPS, ALAD, HAAO | CYP2D6 458/4885HDAC3 1096/4885HDAC1 872/4885 |
| US-20230105745-A1 | CYCLOALKYL AND HETERO-CYCLOALKYL INHIBITORS, PREPARATION METHODS THEREFOR, AND USE THEREOF | KRAS, NRAS, WEE1 | CYP2D6 741/4885HDAC3 4753/4885HDAC1 3774/4885 |
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | ACKR3, KIT, C3AR1 | CYP2D6 401/4885HDAC3 2206/4885HDAC1 3221/4885 |
| US-11459327-B1 | Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and use thereof | KRAS, NRAS, WEE1 | CYP2D6 741/4885HDAC3 4753/4885HDAC1 3774/4885 |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | CYP2D6 2283/4885HDAC3 1404/4885HDAC1 1151/4885 |
| US-20230212148-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | CPSF6, NFATC1, CPSF1 | CYP2D6 494/4885HDAC3 2698/4885HDAC1 1930/4885 |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | CCR10, CCR1, CCR3 | CYP2D6 496/4885HDAC3 187/4885HDAC1 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.